8.20Open8.20Pre Close0 Volume5 Open Interest5.00Strike Price0.00Turnover391.14%IV-5.78%PremiumOct 18, 2024Expiry Date9.01Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9430Delta0.0088Gamma1.47Leverage Ratio-0.0369Theta0.0021Rho1.39Eff Leverage0.0038Vega
Travere Therapeutic Stock Discussion
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address ...
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
🤔 no action even for AH.
No comment yet